Terence Hall
AVEO Oncology (United States)(US)
Publications by Year
Research Areas
Fibroblast Growth Factor Research, PI3K/AKT/mTOR signaling in cancer, Lung Cancer Treatments and Mutations, Advanced Breast Cancer Therapies, Kruppel-like factors research
Most-Cited Works
- → Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma(2018)376 cited
- → Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092(2015)121 cited
- → Discovery and Optimization of a Series of 3-(3-Phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amines: Orally Bioavailable, Selective, and Potent ATP-Independent Akt Inhibitors(2012)99 cited
- → Preclinical Activity of ARQ 087, a Novel Inhibitor Targeting FGFR Dysregulation(2016)84 cited
- → ARQ 087, an oral pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced intrahepatic cholangiocarcinoma (iCCA) with FGFR2 genetic aberrations.(2017)30 cited
- → In-vitro and in-vivo combined effect of ARQ 092, an AKT inhibitor, with ARQ 087, a FGFR inhibitor(2017)28 cited
- → Antitumor Activity of a Novel Fibroblast Growth Factor Receptor Inhibitor for Intrahepatic Cholangiocarcinoma(2019)21 cited
- → ARQ 087 inhibits FGFR signaling and rescues aberrant cell proliferation and differentiation in experimental models of craniosynostoses and chondrodysplasias caused by activating mutations in FGFR1, FGFR2 and FGFR3(2017)19 cited
- → Phase 1, first-in-human study of ARQ 087, an oral pan-Fibroblast Growth Factor Receptor (FGFR) inhibitor, in patients (pts) with advanced solid tumors.(2015)8 cited
- → Tolerability and preliminary activity of the potent, selective, oral CDK7 inhibitor SY-5609 in combination with fulvestrant in patients with advanced hormone receptor-positive (HR+), HER2- breast cancer (BC).(2023)3 cited